Macular Edema News and Research

RSS
Regeneron receives FDA acceptance for EYLEA injection for treatment of macular edema

Regeneron receives FDA acceptance for EYLEA injection for treatment of macular edema

Aerpio Therapeutics doses first patient in AKB-9778 Phase 2 trial for diabetic macular edema treatment

Aerpio Therapeutics doses first patient in AKB-9778 Phase 2 trial for diabetic macular edema treatment

SMC accepts ILUVIEN for use within NHS Scotland to treat vision impairment

SMC accepts ILUVIEN for use within NHS Scotland to treat vision impairment

pSivida announces financial results for second quarter 2014

pSivida announces financial results for second quarter 2014

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

People with diabetes at risk of developing diabetic macular edema during their lifetime

People with diabetes at risk of developing diabetic macular edema during their lifetime

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

EYLEA Injection gets approval in Japan for treatment of macular edema following CRVO

EYLEA Injection gets approval in Japan for treatment of macular edema following CRVO

Regeneron announces topline results from Phase 3 study of EYLEA Injection in patients with Macular Edema following BRVO

Regeneron announces topline results from Phase 3 study of EYLEA Injection in patients with Macular Edema following BRVO

Allegro receives FDA IND approval to initiate Phase II clinical studies of ALG-1001 in AMD, VMT patients

Allegro receives FDA IND approval to initiate Phase II clinical studies of ALG-1001 in AMD, VMT patients

Sun Pharma, Intrexon partner to develop controllable gene-based therapies for ocular diseases

Sun Pharma, Intrexon partner to develop controllable gene-based therapies for ocular diseases

New laser provides better treatment for eye diseases in diabetes patients

New laser provides better treatment for eye diseases in diabetes patients

ThromboGenics, Bicycle to develop and commercialize novel drugs for ophthalmic diseases

ThromboGenics, Bicycle to develop and commercialize novel drugs for ophthalmic diseases

European Commission approves EYLEA for treatment of visual impairment due to macular edema following CRVO

European Commission approves EYLEA for treatment of visual impairment due to macular edema following CRVO

Regeneron, Bayer report positive results from Phase 3 VIVID-DME and VISTA-DME trials of EYLEA for DME

Regeneron, Bayer report positive results from Phase 3 VIVID-DME and VISTA-DME trials of EYLEA for DME

Ico Therapeutics completes Phase 2 iDEAL study for treatment of diabetic macular edema

Ico Therapeutics completes Phase 2 iDEAL study for treatment of diabetic macular edema

pSivida reports that NICE issues draft guidance for use of ILUVIEN for pseudophakic patients with DME

pSivida reports that NICE issues draft guidance for use of ILUVIEN for pseudophakic patients with DME